‘An in-depth understanding of the customer has always been key to our success. Our revolutionary Safetac® technology was invented in the 1980s as a result of an early ethnographic study. Mölnlycke researcher Tomas Fabo observed patients’ pain and stress during dressing changes, and resolved to do something about it.

Researching throughout the product lifecycle

‘We generate evidence throughout the product lifecycle and use a customer centric approach. This includes evidence to bring product to the market, differentiate it and demonstrate value to the patient, the provider and the payer. Evidence generation is dependent on requirements, and can range from broad observational studies looking at a particular setting or patient group to large randomised controlled trials. We also support localised quality improvement projects to demonstrate to clinicians that what we see in our major studies, they also see in their hands with their patients.

‘It’s fundamental that clinicians can get the right treatment for the right patient at the right time. So we design all data generation to capture healthcare economic endpoints in order to continually demonstrate the value of our solutions. At Mölnlycke, we want healthcare systems to use their budgets to get the best healthcare value they can.

Inspiring product development

‘By setting up studies and participating in them, we not only build the clinical and economic evidence for our solutions, we also drive forward innovation by gathering insights that can inspire product development. For example, Mepilex Border Heel and Sacrum were born out of a number of quality improvement studies into pressure ulcer prevention.

Regulatory and Quality Affairs as enablers

‘I’m also absolutely passionate about quality and regulatory affairs as enablers. At Mölnlycke, we consider standards and regulatory requirements right from when we first conceive a product and determine its path to market. If a product is to be licensed in certain markets, a specific study may be needed in the region. We embrace this, as it means we can develop our products in the knowledge that they work for all demographics.

Maximising value through evidence

‘As Chief Medical Officer, I sit on Mölnlycke’s Executive Leadership Team. That means that voices of the clinician and patient are represented at the top level of the company and drive our strategic intent. As Mölnlycke continues to advance, our new solutions will always be driven by maximising value for clinicians, patients and payers, with insights gathered through evidence.’